OmniAB Inc (OQ:OABI)
Business Focus: Biotechnology & Medical Research
Apr 22, 2024 08:00 am ET
OmniAb to Report First Quarter 2024 Financial Results on May 9
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Mar 20, 2024 04:05 pm ET
OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
Feb 26, 2024 08:00 am ET
OmniAb to Report Fourth Quarter 2023 Financial Results on March 20
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Feb 20, 2024 08:00 am ET
OmniAb to Participate in Two Investor Conferences in March
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March.
Dec 14, 2023 04:30 pm ET
OmniAb Presents New Scientific Data on its OmnidAb™ Platform at the 2023 Antibody Engineering & Therapeutics Conference
OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering
Nov 09, 2023 05:55 pm ET
OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event
OmniAb, Inc. (Nasdaq: OABI) held its first Research & Technology virtual event earlier today, during which members of the management team reviewed the Company’s technology offerings and highlighted the launch of OmnidAb, the industry’s first and only transgenic chicken producing single domain antibodies (sdAbs). The archived webcast and speaker slides will be available on the
Nov 09, 2023 08:00 am ET
OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates.
Nov 02, 2023 08:00 am ET
OmniAb to Participate in Two Investor Conferences in November
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in November.
Nov 01, 2023 09:00 am ET
OmniAb Appoints Steve Love to its Board of Directors
OmniAb, Inc. (NASDAQ: OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb’s Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors.
Oct 31, 2023 04:28 pm ET
OmniAb Announces Agenda for its Research & Technology Virtual Event
OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9th beginning at 11:00 a.m. Eastern time. The two-hour event will include an update on the company’s technology offerings, a review of third quarter financial results, which will be announced earlier that morning, and a Q&A session.
Oct 12, 2023 08:00 am ET
OmniAb to Hold Research & Technology Virtual Event on November 9
OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time. The event is expected to last approximately two hours and will include a review of the company’s latest technology offerings and financial results for the three and nine months ended September 30, 2023, which will be announced earlier that morning.
Sep 05, 2023 08:00 am ET
OmniAb to Participate in Two Investor Conferences in September
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in September.
Aug 10, 2023 04:05 pm ET
OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates.
Aug 07, 2023 04:05 pm ET
OmniAb Announces the Passing of Director Sunil Patel
OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week. The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil’s many contributions to OmniAb.
Jul 31, 2023 08:00 am ET
OmniAb to Report Second Quarter 2023 Financial Results on August 10
OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
May 17, 2023 04:05 pm ET
OmniAb Launches OmniDeep™ at the PEGS Boston Conference and Expo
OmniAb, Inc. (NASDAQ: OABI) announced the launch of OmniDeep™ at the 19th Annual PEGS Boston Conference and Expo: The Essential Protein Engineering & Cell Therapy Summit. The Company introduced elements of its OmniDeep platform at 1:10 p.m. Eastern time today in a presentation by Bob Chen, Ph.D., OmniAb's Senior Director, Systems Engineering.
May 11, 2023 07:00 am ET
OmniAb Reports First Quarter 2023 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates.
May 01, 2023 08:00 am ET
OmniAb to Report First Quarter 2023 Financial Results on May 11
OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time.
Apr 25, 2023 08:00 am ET
OmniAb to Participate in Upcoming Investor Conferences in May
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May.
Mar 30, 2023 04:05 pm ET
OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.
Mar 09, 2023 08:00 am ET
OmniAb to Report Fourth Quarter 2022 Financial Results on March 30
OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Feb 07, 2023 08:00 am ET
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three upcoming investor conferences.
Dec 01, 2022 08:47 am ET
Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb’s Picobodies™, via a Collaboration Agreem
Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”) today announced the development of proprietary targeted biologics, Knob Quatrabodies™ (HSB-1940) against PD-1. Hillstream signed separate collaboration agreements with a...
Nov 15, 2022 07:00 am ET
OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) until its spin-off as an independent publicly traded company as of November 1, 2022. As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found
Nov 03, 2022 08:00 am ET
OmniAb to Participate in Two Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences.
Nov 02, 2022 07:00 am ET
OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell
OmniAb, Inc. (NASDAQ: OABI) today announced its Chief Executive Officer Matt Foehr will ring the opening bell of the Nasdaq Stock Market in a ceremony today at 9:30 a.m. Eastern time. He will be joined by members of OmniAb’s leadership team and Board of Directors to celebrate its listing on the exchange, where regular trading will begin under the ticker OABI on November 2, 2022.
Nov 01, 2022 04:01 pm ET
Ligand Announces Completion of OmniAb Spin-Off
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company. OmniAb will begin regular-way trading November 2, 2022 on NASDAQ under the stock ticker symbol “OABI.” Ligand continues to trade under the stock ticker symbol “LGND.”
Nov 01, 2022 04:01 pm ET
OmniAb Announces Completion of Spin-Off and Business Combination
OmniAb, Inc. (NASDAQ: OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ: AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol “OABI.”
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.